The efficacy and safety of mepolizumab in severe eosinophilic asthma: a literature review


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The review presents modern ideas about severe eosinophilic bronchial asthma (SEBA); in this disease, a central role in the regulation and increased activation of eosinophils is played by the cytokines associated with this asthma phenotype, including interleukin-5. In this regard, in recent years, targeted therapy for SEBA using anti-interleukin-5 drugs, including mepolizumab, has been actively developing. A number of clinical studies carried out in accordance with the modern requirements of evidence-based medicine have demonstrated that a decrease in the level of eosinophilia that develops during treatment with mepolizumab in patients with SEBA is accompanied by a decrease in the frequency of exacerbations, improved control of the disease and lung function, and improved quality of life. The clinical effect of mepolizumab is independent of atopic status and eosinophilia level. Given the frequent combination of SEBA with polypous rhinosinusitis, data on the clinical efficacy of mepolizumab in this comorbid pathology, which significantly aggravate the condition of patients, deserve attention. The results of the studies analyzed and generalized in the review allow the authors to conclude that the wider introduction of mepolizumab for the treatment of SEBA patients is feasible.

Texto integral

Acesso é fechado

Sobre autores

B. Chernyak

Irkutsk State Medical Academy of Postgraduate Education - Branch of the Russian Medical Academy of Continuous Professional Education

Email: ba.chernyak@gmail.com
MD, Professor, Head of the Department of Clinical Allergology and Pulmonology

I. Vorzheva

Irkutsk State Medical Academy of Postgraduate Education - Branch of the Russian Medical Academy of Continuous Professional Education

Bibliografia

  1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Update 2019. Available from: https://www.ginasthma. org. Accessed 2019 Sep 15.
  2. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-25. doi: 10.1038/nm.2678.
  3. Chung K.F., Wenzel S.E., Brozek J.L., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343- 73. doi: 10.1183/09031936.00202013.
  4. Difficult-to-treat & severe asthma in adolescent and adult patients. Diagnosis and management. GINA 2019. Available from: http://www. ginasthma.org. Accessed2019 Sep 15.
  5. Барановская Т.В., Белевский А.С., Восканян А.Г. и др. Тяжелая бронхиальная астма-2018. Согласительный доклад объединенной группы экспертов Ассоциации русскоговорящих специалистов в области респираторной медицины, Российского респираторного общества, Российской ассоциации аллергологов и клинических иммунологов. Практическая пульмонология. 2018;3:52-64.
  6. Федеральные клинические рекомендации по бронхиальной астме 2019. Доступно по: https://www.spulmo.ru. Ссылка активна на 15.09.2019
  7. Moore W.C., Meyers D.A, Wenzel S.E., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315-23. doi: 10.1164/rccm.200906-08960C.
  8. Lefaudeux D., De Meulder B., Loza M.J., et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J. Allergy Clin Immunol. 2017;139:1797-1807. doi: 10.1016/j.jaci.2016.08.048.
  9. Chung K.F. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med. 2018;24:4-10. Doi: 10.1097/ MCP0000000000000434.
  10. Haldar Р. Patient profiles and clinical utility of mepolizumab. Biologics. 2017;11:81-95. doi: 10.2147/BTT.S93954.
  11. Ненашева Н.М. Бронхиальная астма. Современный взгляд на проблему. М.: ГЭОТАР-Медиа 2018. 304 с.
  12. Wenzel S.E., Schwartz L.B., Langmack E.L. et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001-8.
  13. Gibson PG., Simpson J.L., Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001;119:1329-36.
  14. Price D.B., Rigazio A., Campbell J.D., et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849-58. doi: 10.1016/S2213-2600(15)00367-7.
  15. de Groot J.C., Storm H., Amelink M., et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016;2:pii: 00100-2015.
  16. Schleich F.N., Chevremont A., Paulus V., et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44:97-108. doi: 10.1183/09031936.00201813.
  17. Buhl R., Humbert M., Bjermer L., et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49:pii: 1700634. doi: 10.1183/13993003.00634-2017.
  18. Черняк Б.А., Воржева И.И. Эозинофилы и аллергия. Российский аллергологический журнал. 2013;4:3-12.
  19. Woessner K.M. Update on Aspirin-Exacerbated Respiratory Disease. Curr Allergy Asthma Rep. 2017;17: 2. doi: 10.1007/s11882-017-0673-6.
  20. Воржева И.И., Черняк Б.А. Аспирин-индуцированное респираторное заболевание: механизмы развития, диагностика и лечение. Фарматека. 2018;8:24-33. Doi:https://dx.doi. org/10.18565/pharmateca.2018.8.24-33.
  21. Pelaia C., Vatrella A., Busceti M.T., et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des Devel Ther. 2017;11:3137-44. doi: 10.2147/DDDT. S150656.
  22. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav. ru. Ссылка активна на 15.09.2019.
  23. Haldar P., Brightling C.E., Hargadon B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl J. Med. 2009;360:973-84. Doi: 10.1056/ NEJMoa0808991.
  24. Nair P., Pizzichini M.M., Kjarsgaard M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl J. Med. 2009;360:985-93. Doi: 10.1056/ NEJMoa0805435.
  25. Pavord I.D., Korn S., Howarth P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-59. doi: 10.1016/S0140-6736(12)60988-X.
  26. Ortega H.G., Liu M.C., Pavord I.D., et al; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl J. Med. 2014;371:1198-207. Doi: 10.1056/ NEJMoa1403290.
  27. Bel E.H., Wenzel S.E., Thompson PJ., et al. SIRIUS investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl J. Med. 2014;371:1189-97. Doi: 10.1056/ NEJMoa1403291.
  28. Albers F.C., Price R.G., Smith S.G., Yancey S.W. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J. Allergy Clin Immunol. 2017;140:1464-66. Doi: 10.1016/j. jaci.2017.06.010.
  29. Lugogo N., Domingo C., Chanez P., et al. Longterm Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther. 2016;38:2058-70. Doi: 10.1016/j. clinthera.2016.07.010.
  30. Farne H.A., Wilson A., Powell C., et al. Anti-IL5 therapies for asthma (Review). Cochrane Database Syst Rev. 2017;9:CD010834. doi: 10.1002/14651858.CD010834.pub3.
  31. Khatri S., Moore W., Gibson PG., et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J. Allergy Clin Immunol. 2019;143:1742-51. Doi: 10.1016/j. jaci.2018.09.033.
  32. Chupp G.L., Bradford E.S., Albers F.C., et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase 3b trial. Lancet Respir Med. 2017;5:390-400. doi: 10.1016/S2213-2600(17)30125-X.
  33. Ortega H.G., Yancey S.W., Mayer B., et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549-56. doi: 10.1016/S2213-2600(16)30031-5.
  34. Albers F.C., Mullerova H., Gunsoy N.B., et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J. Asthma. 2018;55:152-60. doi: 10.1080/02770903.2017.1322611.
  35. Tran T.N., Zeiger R.S., Peters S.P., et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116:37-42. Doi: 10.1016/j. anai.2015.10.027.
  36. Bachert C., Zhang N., Patou J., et al. Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol 2008;8:34-8. Doi: 10.1097/ ACI.0b013e3282f4178f.
  37. Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy. 2009;39:1145-51. doi: 10.1111/j.1365-2222.2009.03298.x.
  38. Cockle S.M., Stynes G., Gunsoy N.B., et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med. 2017;123:140-48. Doi: 10.1016/j. rmed.2016.12.009.
  39. Nachef Z., Krishnan A., Mashtare T., et al. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis. J. Asthma. 2018;55:89-100. doi: 10.1080/02770903.2017. 1306548.
  40. Massoth L., Anderson C., McKinney K.A. Asthma and Chronic Rhinosinusitis: Diagnosis and Medical Management. MedSci (Basel). 2019;7:pii: E53. doi: 10.3390/medsci7040053.
  41. Avdeeva K., Fokkens W. Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps. Curr Allergy Asthma Rep. 2018;18:25. doi: 10.1007/s11882-018-0776-8.
  42. Gevaert P., Van Bruaene N., Cattaert T., et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin Immunol. 2011;128:989-95. doi: 10.1016/j.jaci.2011.07.056.
  43. Ren L., Zhang N., Zhang L., Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art. World Allergy Organ J. 2019;12:100050. Doi: 10.1016/j. waojou.2019.100050.
  44. Bachert C., Sousa A.R., Lund V.J., et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. J. Allergy Clin Immunol. 2017;140:1024-31. Doi: 10.1016/j. jaci.2017.05.044.
  45. Tuttle K.L., Buchheit K.M., Laidlaw T.M., Cahill K.N. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J. Allergy Clin Immunol Pract. 2018;6:1045-47. Doi: 10.1016/j. jaip.2018.01.038.
  46. Cavaliere C., Incorvaia C., Frati F., et al. Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps. Clin MolAllergy. 2019;17:3. doi: 10.1186/s12948- 019-0106-2.
  47. Sanchez-Jareno M., Barranco P., Romero D., et al. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics. J. Investig Allergol Clin Immunol. 2019; 29:79-81. doi: 10.18176/jiaci.0340.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies